妊娠期大面积肺栓塞的溶栓治疗
妊娠女性因凝血、纤溶及静脉血流变化而面临静脉血栓栓塞高风险,肺栓塞是美国孕产妇死亡首位原因。妊娠女性被溶栓临床试验排除,现有数据仅来自病例报告或病例系列。本文综述妊娠期大面积肺栓塞溶栓(全身或导管定向)的所有报告,总结妊娠期血栓栓塞风险、比较溶栓药物,并给出该特殊人群大面积肺栓塞的管理建议。总体报告提示溶栓与有益结局相关且并发症风险相对较低,但证据质量低,需临床判断个体风险获益。
要点
- 肺栓塞是美国孕产妇死亡首位原因,妊娠女性静脉血栓栓塞风险高。
- 妊娠女性被溶栓临床试验排除,现有数据仅来自病例报告或病例系列。
- 报告提示溶栓与有益结局相关且并发症风险相对较低,但证据质量低。
核心结论
- 报告提示妊娠期大面积肺栓塞使用溶栓药物与有益结局相关且并发症风险相对较低,但证据质量低,需个体化评估风险获益。
研究设计与样本
- 综述妊娠期大面积肺栓塞患者使用全身或导管定向溶栓的所有病例报告或病例系列。
主要发现
- 妊娠女性被溶栓临床试验排除,现有数据仅来自病例报告或病例系列。
- 报告提示溶栓药物与有益结局相关且并发症风险相对较低。
临床怎么用
- 妊娠期大面积肺栓塞可考虑溶栓治疗,但需基于个体患者风险获益评估进行临床判断。
局限性
- 证据质量低,数据仅来自病例报告或病例系列。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pregnant women are at high risk for venous thromboembolism, including pulmonary embolism (PE), given expected changes in coagulation, fibrinolysis, and venous blood flow. In fact, PE is the leading cause of maternal death in the United States. Nonpregnant patients who develop PE with hypotension or show signs of deterioration after anticoagulation receive thrombolytics as a standard of care. Pregnant women, however, have been excluded from clinical trials with thrombolytics, and all data available in this population are published as case reports or case series. We reviewed all reports of thrombolytics, systemic or catheter directed, used in pregnant patients with massive PE. This article summarizes the risks for thromboembolism in pregnancy, compares and contrasts thrombolytic agents in this setting, and provides a recommendation for management of massive PE in this special population. Overall, reports suggest that the use of these agents is associated with beneficial outcomes and a relatively low risk of complications. The quality of this evidence is low, and clinical judgment is required to assess individual patients for risks versus benefits of thrombolysis.
引用
- Heavner MS, Zhang M, Bast CE, et al. Thrombolysis for Massive Pulmonary Embolism in Pregnancy. Pharmacotherapy. 2017. PMID: 28891082. doi:10.1002/phar.2025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。